Gynaecologic effects of Tamoxifen

Dennis Yi-Shin Kuo, Carolyn D. Runowicz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalMedical Oncology
Volume12
Issue number2
DOIs
StatePublished - Jun 1995

Fingerprint

Tamoxifen
Estrogen Antagonists
Uterine Neoplasms
Myometrium
Controlled Clinical Trials
Vagina
Endometrium
Estrogens
Placebos
Breast Neoplasms
Recurrence
Survival
Pharmaceutical Preparations
Therapeutics

Keywords

  • breast cancer
  • estrogen effect
  • tamoxifen
  • uterine cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Gynaecologic effects of Tamoxifen. / Kuo, Dennis Yi-Shin; Runowicz, Carolyn D.

In: Medical Oncology, Vol. 12, No. 2, 06.1995, p. 87-94.

Research output: Contribution to journalArticle

Kuo, Dennis Yi-Shin ; Runowicz, Carolyn D. / Gynaecologic effects of Tamoxifen. In: Medical Oncology. 1995 ; Vol. 12, No. 2. pp. 87-94.
@article{395616be49734ca2ab5e0591dbddd72e,
title = "Gynaecologic effects of Tamoxifen",
abstract = "Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.",
keywords = "breast cancer, estrogen effect, tamoxifen, uterine cancer",
author = "Kuo, {Dennis Yi-Shin} and Runowicz, {Carolyn D.}",
year = "1995",
month = "6",
doi = "10.1007/BF01676708",
language = "English (US)",
volume = "12",
pages = "87--94",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Gynaecologic effects of Tamoxifen

AU - Kuo, Dennis Yi-Shin

AU - Runowicz, Carolyn D.

PY - 1995/6

Y1 - 1995/6

N2 - Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.

AB - Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.

KW - breast cancer

KW - estrogen effect

KW - tamoxifen

KW - uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=0028788985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028788985&partnerID=8YFLogxK

U2 - 10.1007/BF01676708

DO - 10.1007/BF01676708

M3 - Article

VL - 12

SP - 87

EP - 94

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 2

ER -